中西医结合肝病杂志2025，Vol.35Issue(5)：538-542,5.DOI:10.3969/j.issn.1005-0264.2025.005.002
疏肝健脾化瘀汤联合恩替卡韦对乙型肝炎肝硬化患者肠道菌群及T淋巴细胞的影响
Impacts of Shugan Jianpi Huayu decoction combined with entecavir on intestinal microbiota and T lymphocytes in patients with hepatitis B cirrhosis
摘要
Abstract
Objective:By observing the clinical efficacy of Entecavir and Shuganjianpi Huayu decoction in the treatment of hepatitis B cirrhosis patients,and analyzing the impacts of the above two drugs on intestinal microbiota and T lymphocytes in patients with cirrhosis.Methods:A total of 80 patients with compensated hepatitis B cirrhosis admitted to the Third People's Hospital of Nantong City from January 2022 to December 2023 were selected for the study.Using a table of random numbers,the observation group(40 cases,given oral treatment with Entecavir dispersing tablets,1 tablet/time,1 time/day)and the control group(40 cases,given treatment with Shugan-Jianpi-huayu decoction+Entecavir dispersing tablets,1 dose/time,2 times/day)were divided into 1∶1 groups.Both groups were treated continuously for 8 weeks.The clinical efficacy,liver function indicators,gut microbiota(Bifidobacterium,Bacteroidetes,Escherichia coli,Clostridium perfringens,Lactobacillus,Enterococcus),and peripheral blood T lymphocyte indicators were compared between the two groups before and after treatment.Results:The total effective rate of the observation group was greatly higher than that of the control group(x2=6.135,P=0.013).After treatment,liver function and immune function were significantly improved in both groups and more improved in the observation group(P＜0.05).There were significant differences in Bacillus perfringens between the two groups before treatment(P＜0.05),but no differences in other strains(bifidobacterium,Lactobacillus,eubacillus,Bacteroides,Enterococcus,Escherichia coli)(P＞0.05).After treatment,in the observation group,except for Bacillus perfringens and Escherichia coli significantly decreased(P＜0.05),other bacteria significantly increased(P＜0.05),and a great decrease in Clostridium perfringens and Escherichia coli(P＜0.05).The control group showed a great increase in Clostridium perfringens,Escherichia coli,and Enterococcus(P＜0.05).Conclusion:The use of these two drugs in the treatment of patients with compensatory cirrhosis can effectively improve the intestinal flora and peripheral blood T-lymphocyte balance.关键词
疏肝健脾化瘀汤/恩替卡韦/肝硬化/肠道菌群/T淋巴细胞Key words
Shugan Jianpi Huayu decoction/entecavir/liver cirrhosis/intestinal microbiota/T lymphocytes分类
医药卫生引用本文复制引用
翁佳欣,顾尔莉,达坤林,张玉,王忠成..疏肝健脾化瘀汤联合恩替卡韦对乙型肝炎肝硬化患者肠道菌群及T淋巴细胞的影响[J].中西医结合肝病杂志,2025,35(5):538-542,5.基金项目
南通市卫生健康委员会科研课题(No.MSZ2023046),江苏省中医药科技发展计划项目(No.MS2022093),社会民生科技计划-面上项目(No.MSZ2022026) （No.MSZ2023046）
